Following FL/GM-DC therapy, a substantial expansion of Tex and pTex was observed, accompanied by upregulation of immune checkpoint molecules such as Pdcd1 and Lag3. These findings suggest that combining FL/GM-DC therapy with immune checkpoint inhibitors may prolong the anti-tumor activity of CD8+ T cells, further enhancing therapeutic efficacy. The gene discussed is PDCD1; the disease is neoplasm.